Quest Partners LLC Has $89,000 Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)

Quest Partners LLC trimmed its position in United Therapeutics Co. (NASDAQ:UTHR) by 30.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 279 shares of the biotechnology company’s stock after selling 125 shares during the quarter. Quest Partners LLC’s holdings in United Therapeutics were worth $89,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Access Investment Management LLC lifted its holdings in shares of United Therapeutics by 0.8% in the second quarter. Access Investment Management LLC now owns 7,265 shares of the biotechnology company’s stock worth $2,314,000 after acquiring an additional 55 shares during the last quarter. MBM Wealth Consultants LLC lifted its stake in United Therapeutics by 2.7% in the 1st quarter. MBM Wealth Consultants LLC now owns 2,241 shares of the biotechnology company’s stock valued at $515,000 after purchasing an additional 59 shares during the last quarter. Fifth Third Bancorp boosted its position in United Therapeutics by 13.2% in the second quarter. Fifth Third Bancorp now owns 585 shares of the biotechnology company’s stock valued at $186,000 after buying an additional 68 shares in the last quarter. Wealth Enhancement Advisory Services LLC grew its stake in shares of United Therapeutics by 3.1% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 2,666 shares of the biotechnology company’s stock worth $849,000 after buying an additional 81 shares during the last quarter. Finally, Janiczek Wealth Management LLC increased its holdings in shares of United Therapeutics by 21.1% during the first quarter. Janiczek Wealth Management LLC now owns 482 shares of the biotechnology company’s stock worth $111,000 after buying an additional 84 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

United Therapeutics Trading Up 0.0 %

UTHR opened at $345.02 on Wednesday. The stock has a market cap of $15.30 billion, a PE ratio of 16.31, a price-to-earnings-growth ratio of 1.23 and a beta of 0.57. The company has a quick ratio of 4.18, a current ratio of 4.35 and a debt-to-equity ratio of 0.02. United Therapeutics Co. has a twelve month low of $208.62 and a twelve month high of $366.08. The company has a fifty day moving average of $337.29 and a 200-day moving average of $288.79.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share for the quarter, missing the consensus estimate of $6.33 by ($0.48). The business had revenue of $714.90 million during the quarter, compared to the consensus estimate of $691.87 million. United Therapeutics had a return on equity of 18.82% and a net margin of 40.87%. The business’s revenue was up 19.8% on a year-over-year basis. During the same period last year, the business posted $5.24 earnings per share. On average, sell-side analysts predict that United Therapeutics Co. will post 24.86 EPS for the current year.

Insiders Place Their Bets

In other United Therapeutics news, CEO Martine A. Rothblatt sold 3,600 shares of the stock in a transaction that occurred on Friday, June 21st. The stock was sold at an average price of $313.91, for a total transaction of $1,130,076.00. Following the transaction, the chief executive officer now directly owns 130 shares in the company, valued at approximately $40,808.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, CEO Martine A. Rothblatt sold 3,600 shares of the company’s stock in a transaction dated Friday, June 21st. The shares were sold at an average price of $313.91, for a total transaction of $1,130,076.00. Following the transaction, the chief executive officer now owns 130 shares in the company, valued at $40,808.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Raymond Dwek sold 5,000 shares of the firm’s stock in a transaction dated Friday, August 2nd. The shares were sold at an average price of $325.35, for a total value of $1,626,750.00. Following the completion of the sale, the director now owns 1,750 shares of the company’s stock, valued at $569,362.50. The disclosure for this sale can be found here. Over the last three months, insiders sold 114,522 shares of company stock worth $37,671,474. 12.50% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on UTHR. StockNews.com lowered United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, August 2nd. Bank of America cut their price target on United Therapeutics from $303.00 to $280.00 and set an “underperform” rating on the stock in a research note on Thursday, August 1st. Morgan Stanley downgraded United Therapeutics from an “overweight” rating to an “equal weight” rating and upped their price objective for the company from $310.00 to $321.00 in a research note on Thursday, July 11th. Wells Fargo & Company lifted their target price on shares of United Therapeutics from $350.00 to $380.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 20th. Finally, TD Cowen upped their price target on shares of United Therapeutics from $270.00 to $350.00 and gave the company a “buy” rating in a research report on Thursday, July 11th. One analyst has rated the stock with a sell rating, three have given a hold rating and ten have assigned a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $350.36.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.